Design Therapeutics (NASDAQ:DSGN) Shares Gap Down to $27.61

Design Therapeutics, Inc. (NASDAQ:DSGN) gapped down before the market opened on Wednesday . The stock had previously closed at $27.61, but opened at $26.73. Design Therapeutics shares last traded at $27.59, with a volume of 340 shares traded.

Several analysts recently weighed in on DSGN shares. The Goldman Sachs Group started coverage on Design Therapeutics in a report on Tuesday, April 20th. They issued a “neutral” rating and a $28.00 price objective for the company. Piper Sandler started coverage on Design Therapeutics in a report on Tuesday, April 20th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, SVB Leerink started coverage on Design Therapeutics in a report on Tuesday, April 20th. They issued an “outperform” rating and a $36.00 price objective for the company.

The stock’s fifty day moving average price is $25.47.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Monday, May 10th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.25). As a group, research analysts anticipate that Design Therapeutics, Inc. will post -0.85 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new position in Design Therapeutics in the first quarter valued at approximately $248,000. Teachers Retirement System of The State of Kentucky acquired a new position in Design Therapeutics in the first quarter valued at approximately $248,000. Alpine Global Management LLC acquired a new position in Design Therapeutics in the first quarter valued at approximately $401,000. TD Asset Management Inc. acquired a new position in shares of Design Therapeutics during the first quarter worth approximately $638,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Design Therapeutics during the first quarter worth approximately $702,000. Institutional investors own 45.76% of the company’s stock.

About Design Therapeutics (NASDAQ:DSGN)

Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.

Further Reading: Dividend Reinvestment Plan (DRIP)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.